AnTolRx is a Cambridge, Mass.-based research and development biotechnology company focused on immune tolerance with active programs in Type 1 Diabetes, Rheumatoid Arthritis, Inflammatory Bowel Disease, Celiac Disease, and various dermatology diseases including Pemphigus Vulgaris. AnTolRx's antigen-specific immune tolerance technology also has potential to block immune responses to foreign proteins, certain therapeutic recombinant proteins and viral gene therapy products. AnTolRx's proprietary formulation co-delivers an immunomodulatory aryl hydrocarbon receptor agonist with specific antigens to generate disease specific Tregs to treat immunological disorders. The AnTolRx technology expects to overcome safety concerns of products that generate general immune suppression. AnTolRx expects to nominate candidates to treat additional immune disorders in 2019. AnTolRx, Inc. was founded in 2016 by Professor Francisco Quintana, Dr. Satish Jindal and Mark Carthy with initial equity investment from Pfizer Inc., JDRF International and Orion Equity Partners, LLC.
View Top Employees from AnTolRx, Inc.Website | https://antolrx.com |
Revenue | $1 million |
Funding | $5 million |
Employees | 11 (0 on RocketReach) |
Founded | 2015 |
Address | 1400 W, Ste 14303, Cambridge, Massachusetts 02139, US |
Phone | (617) 902-0601 |
Technologies |
JavaScript,
HTML,
PHP
+6 more
(view full list)
|
Industry | Biotechnology, Investment Banking, Pharmaceuticals, Science and Engineering, Construction, Healthcare, Health Care |
Competitors | ARUP Laboratories, Entelos, Exagen Diagnostics Inc, Sagimet Biosciences, True Health |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular AnTolRx, Inc. employee's phone or email?
The AnTolRx, Inc. annual revenue was $1 million in 2023.
AnTolRx, Inc. is based in Cambridge, Massachusetts.
The NAICS codes for AnTolRx, Inc. are [3254, 32541, 32, 325].
The SIC codes for AnTolRx, Inc. are [28, 283].